Evidence map›Paper›PMID 32821094›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2020

Highlights of an Expert Advisory Board on Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD) in Latin America.

Laura Naranjo, Carlos A Torres-Duque, Daniel Colodenco, Gustavo Lopardo, Pablo Rodriguez, Aldo Agra de Albuquerque-Neto, Rafael J Hernandez-Zenteno, Luis Septien, Reynaldo Chandler, Eduardo Ortega-Barria and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Laura NaranjoGSK, Panama City, Panama.
Carlos A Torres-DuqueFundación Neumológica Colombiana, Bogota, Colombia.ORCID 0000-0003-0004-8955
Daniel ColodencoDirector of Pneumology Specialization Course, University of Buenos Aires, Buenos Aires, Argentina.
Gustavo LopardoFUNCEI-Bernardo Houssay Hospital, Buenos Aires, Argentina.ORCID 0000-0002-0886-2380
Pablo RodriguezPulmonary and Critical Care Medicine, CEMIC, Buenos Aires, Argentina.ORCID 0000-0002-3254-2213
Aldo Agra de Albuquerque-NetoPulmonary Rehabilitation Unit, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.ORCID 0000-0002-0382-6911
Rafael J Hernandez-ZentenoMSc Head of COPD Clinic at National Institute of Respiratory Diseases, Mexico City, Mexico.ORCID 0000-0002-8710-160X
Luis SeptienPulmonary and Critical Care Division, National Institute of Nutrition Salvador Zubiran, Mexico City, Mexico.
Reynaldo ChandlerEducation and Investigation Coordination Unit, San Miguel Arcangel Hospital, Ministry of Health, Panama City, Panama.
Eduardo Ortega-BarriaGSK, Panama City, Panama.
Patricia JuliaoGSK, Panama City, Panama.ORCID 0000-0001-6241-483X
Adriana Guzman-HolstGSK, Panama City, Panama.ORCID 0000-0002-6753-2541
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno · ARFundación Centro de Estudios Infectológicos · ARFundación Neumológica Colombiana · COInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXNational Institute of Cardiovascular Diseases · BDUniversidad de Buenos Aires · ARUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a preventable and usually progressive lung disease that affects millions of people worldwide and is the sixth leading cause of death in the Americas. Viral and bacterial respiratory tract infections and air pollution may cause acute exacerbations of COPD (AE-COPD) ranging from mild, moderate to severe. The greatest proportion of the overall COPD burden on the health system is due to disease exacerbations. There is limited evidence regarding the etiology and burden of AE-COPD in Latin America (LATAM). Methods: To respond to this gap in evidence, an Advisory Board with regional pneumologists and infectious disease experts was convened in September 2018 in Panama City, Panama, to: 1) review the burden of AE-COPD in LATAM; 2) evaluate the etiology of AE-COPD in LATAM; and 3) assess and compare the local/regional guidelines to confirm the etiology, characterize, and manage AE-COPD. Results: The results of the meeting showed that there is a high prevalence of AE-COPD in LATAM countries, limited evidence on etiology data, and discrepancies in the case definitions and symptomology (ie, severity) classifications used in LATAM. Conclusion: The Advisory Board discussions further resulted in recommendations for future research on the impact on the epidemiology and burden of disease, on establishing standardized AE-COPD case definition guidelines, and on studying the etiology of both moderate and severe AE-COPD cases.

Indexed as

Air PollutionPulmonary Disease, Chronic ObstructiveDisease ProgressionHumansLatin AmericaPrevalenceconsensusCOPDdiagnosisepidemiologyetiologyexacerbations

Identifiers

PMID32821094
PMCPMC7418149
OpenAlexW3047266876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.